Department of Radiation Oncology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
Department of Radiation Oncology, Jeju National University Hospital, Jeju National University School of Medicine, Jeju, Korea.
PLoS One. 2018 Sep 28;13(9):e0204918. doi: 10.1371/journal.pone.0204918. eCollection 2018.
To evaluate the potential role of 18F-fluorodeoxyglucose-positron emission tomography/computerized tomography (FDG-PET/CT) for predicting treatment response after radiotherapy (RT) in patients with spinal metastases.
A retrospective analysis was performed of 42 patients with spinal metastases who received RT from January 2010 to December 2014. All patients underwent FDG-PET/CT before and after treatment. Changes in metabolic responses, expressed as the maximum, mean, peak standardized uptake values (SUVmax, SUVmean, SUVpeak), metabolic tumor volume (MTV) and total lesion glycolysis (TLG) were analyzed to determine their association with clinical outcomes.
The median age at the time of spinal metastasis diagnosis was 58 years. Median progression-free survival (PFS) and overall survival after RT were 15 months and 22.4 months, respectively. RT produced a significant decrease in SUVmean (2.27 to 1.41), SUVmax (6.87 to 2.99), SUVpeak (5.75 to 2.33) and TLG (52.84 to 24.17) when compared with the baseline values (p<0.001). The mean pain score decreased from 3.86 before RT to 0.79 after RT (p<0.001). There were significant linear relationships between maximum SUV and pain scores at baseline (r = 0.321, p = 0.038) and after treatment (r = 0.369, p = 0.016) as well as TLG at baseline (r = 0.428, p = 0.005) and after treatment (r = 0.403, p = 0.009). Local progression after treatment was identified in 12 patients (28.6%). Univariate analyses showed that >70% reduction in maximum SUV after treatment was independently associated with good PFS (p = 0.036).
RT is an effective treatment for patients with spinal metastases, and there were significant changes in PET parameters compared with baseline. The metabolic response measured by SUV and TLG changes in FDG-PET/CT correlated with the clinical outcomes, especially with shorter PFS in patients who had higher residual maximum SUV after treatment.
评估 18F-氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描(FDG-PET/CT)在预测接受放射治疗(RT)的脊柱转移瘤患者治疗反应中的潜在作用。
回顾性分析了 2010 年 1 月至 2014 年 12 月期间接受 RT 的 42 例脊柱转移瘤患者。所有患者在治疗前后均行 FDG-PET/CT 检查。分析代谢反应的变化,用最大、平均、峰值标准化摄取值(SUVmax、SUVmean、SUVpeak)、代谢肿瘤体积(MTV)和总病灶糖酵解(TLG)表示,以确定其与临床结局的关系。
脊柱转移瘤诊断时的中位年龄为 58 岁。RT 后中位无进展生存期(PFS)和总生存期分别为 15 个月和 22.4 个月。与基线值相比,SUVmean(2.27 降至 1.41)、SUVmax(6.87 降至 2.99)、SUVpeak(5.75 降至 2.33)和 TLG(52.84 降至 24.17)均显著下降(p<0.001)。RT 前平均疼痛评分为 3.86,RT 后降至 0.79(p<0.001)。基线时最大 SUV 与疼痛评分呈显著线性关系(r = 0.321,p = 0.038),治疗后呈显著线性关系(r = 0.369,p = 0.016),基线时 TLG 与疼痛评分呈显著线性关系(r = 0.428,p = 0.005),治疗后呈显著线性关系(r = 0.403,p = 0.009)。12 例(28.6%)患者治疗后出现局部进展。单因素分析显示,治疗后最大 SUV 减少>70%与良好的 PFS 独立相关(p = 0.036)。
RT 是治疗脊柱转移瘤的有效方法,与基线相比,PET 参数有显著变化。FDG-PET/CT 中 SUV 和 TLG 变化所反映的代谢反应与临床结局相关,尤其是治疗后最大 SUV 残留较高的患者 PFS 更短。